Achieving control of resistant hypertension:Not just the number of blood pressure medications

• 作者: Jian Huang Kara Schmidt Steven Tringali William Kelley
• 来源期刊: 世界高血压杂志
• 学科: 医学
• 关键词: Resistant HYPERTENSION Pseudoresistance MINERALOCORTICOID receptor antagonists Device-based HYPERTENSION treatment Renal DENERVATION Carotid BARORECEPTOR activation therapy Central ARTERIOVENOUS anastomosis
• 年，卷（期）: 2019,（1）
• 页码范围: 1-16
• 页数: 16页
• 分类号: R

摘要

Resistant hypertension (RH) has a prevalence of around 12% and is associated with an increased risk of cardiovascular disease,progression to end-stage renal disease,and even mortality.In 2017,the American College of Cardiology and American Heart Association released updated guidelines that detail steps to ensure proper diagnosis of RH,including the exclusion of pseudoresistance.Lifestyle modifications,such as low salt diet and physical exercise,remain at the forefront of optimizing blood pressure control.Secondary causes of RH also need to be investigated,including screening for obstructive sleep apnea.Notably,the guidelines demonstrate a major change in medication management recommendations to include mineralocorticoid receptor antagonists.In addition to advances in medication optimization,there are several device-based therapies that have been showing efficacy in the treatment of RH.Renal denervation therapy has struggled to show efficacy for blood pressure control,but with a redesigned catheter device,it is once again being tested in clinical trials.Carotid baroreceptor activation therapy (BAT) via an implantable pulse generator has been shown to be effective in lowering blood pressure both acutely and in longterm follow up data,but there is some concern about the safety profile.Both a second-generation pulse generator and an endovascular implant are being tested in new clinical trials with hopes for improved safety profiles while maintaining therapeutic efficacy.Both renal denervation and carotid BAT need continued study before widespread clinical implementation.Central arteriovenous anastomosis has emerged as another possible therapy and is being actively explored.The ongoing pursuit of blood pressure control is a vital part of minimizing adverse patient outcomes.The future landscape appears hopeful for helping patients achieve blood pressure goals not only through the optimization of antihypertensive medications but also through device-based therapies in select individuals.